RxDoctor Payments Data

Andrew Gangemi, MD

Internal Medicine · Philadelphia, PANPI 1386081503

Payments from drug & device makers

$8,374in general payments, 2019–2025

Across 15 payments — averaging $558.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Inogen, Inc.$5K
  • CSL Behring$3K
  • Genentech USA, Inc.$100
  • Mylan Specialty L.p.$74
  • Electromed, Inc.$42
  • Tactile Systems Technology Inc$26
  • plus $59 from 3 others

What the payments were for

  • Speaking & faculty fees$6,78581%
  • Travel & lodging$7038%
  • Food & beverage$7869%
  • Education$1001%

General payments by program year

19
20
21
22
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,374 in reported general payments places this provider in the 90th percentile of 5,705 internal medicine providers in Pennsylvania.

See all internal medicine providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$95,716
Medicare patients
305
Services billed
886

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter214$237,811
Aralast NpAlpha-1-Proteinase Inhibitor11$165,948
OfevNintedanib Esylate12$123,678
Dupixent PenDupilumab25$91,747
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr112$71,438
Dupixent SyringeDupilumab14$47,920
Spiriva RespimatTiotropium Bromide50$43,211
Breztri AerosphereBudesonide/Glycopyr/Formoterol47$40,141
Advair HfaFluticasone Propion/Salmeterol35$30,138
EliquisApixaban23$27,942
Stiolto RespimatTiotropium Br/Olodaterol Hcl29$25,242
Breo ElliptaFluticasone/Vilanterol28$15,407
Bevespi AerosphereGlycopyrrolate/Formoterol Fum23$14,823
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate31$9,699
Albuterol Sulfate HfaAlbuterol Sulfate220$8,504

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimOfev, Spiriva Respimat, Stiolto Respimat$24$192,13191 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 5,705 internal medicine providers in Pennsylvania.

Other internal medicine in Philadelphia

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →